Prolonged rhIL-11 treatment significantly elevates BNP and increases arrhythmia risk in severe thrombocytopenia patients
Background
Patients undergoing cancer chemotherapy frequently develop thrombocytopenia, a condition characterized by dangerously low platelet counts, which can lead to severe bleeding complications. Recombinant human interleukin-11 (rhIL-11) is a common therapeutic option for stimulating platelet production. However, its use has been associated with cardiac side effects, raising concerns, particularly with extended treatment durations. This study addresses the critical gap in understanding the specific cardiac risks of prolonged rhIL-11 therapy, focusing on cardiac biomarkers and arrhythmia incidence.
Study Design
This retrospective cohort study analyzed adult patients treated for severe thrombocytopenia with either recombinant human interleukin-11 (rhIL-11) or recombinant human thrombopoietin (rhTPO) for a minimum of ≥ 5 days between 2015 and 2021. Data were collected at baseline, during treatment, and post-discontinuation. The primary endpoints were changes in serum BNP levels and the occurrence of cardiac arrhythmias. Statistical analyses compared these outcomes between the rhIL-11 group (N=23) and the rhTPO group (N=7).
Results
The rhIL-11 group demonstrated a significant increase in serum BNP levels, rising from a baseline median of 418 pg/mL (IQR: 193-1205) to 3084 pg/mL (IQR: 1446-5000) within one week of treatment (P < 0.01). In contrast, the rhTPO group showed no significant BNP changes (P = NS). Post-discontinuation, BNP levels in the rhIL-11 group decreased to 384.0 pg/mL (IQR: 239.0-460.0) one week later (P < 0.05). Cardiac arrhythmias were documented in 34.8% (8/23) of rhIL-11-treated patients. This risk was strongly duration-dependent: > 83.3% (5/6) of patients treated for more than two weeks developed arrhythmias, and all 3 patients (100%) treated beyond three weeks experienced cardiac complications, including two cases of frequent ventricular tachycardia. The rhTPO group reported no significant BNP changes or arrhythmic events. Kaplan-Meier analysis confirmed a statistically significant divergence in arrhythmia risk profiles between the groups (P < 0.05), with age identified as an independent risk factor.
Key Findings
- rhIL-11 treatment significantly increased serum
BNPlevels from 418 pg/mL to 3084 pg/mL within one week (P < 0.01). - Cardiac arrhythmias occurred in 34.8% (8/23) of rhIL-11-treated patients.
- Arrhythmia risk was duration-dependent: 83.3% of patients treated >2 weeks and 100% treated >3 weeks developed arrhythmias.
- rhTPO treatment showed no significant changes in
BNPor arrhythmia rates. - Age was identified as an independent risk factor for arrhythmia in rhIL-11-treated patients.
Why It Matters
This study provides crucial real-world evidence highlighting the significant cardiac risks associated with prolonged rhIL-11 use, particularly for patients with severe thrombocytopenia. The clear duration-dependent increase in BNP and arrhythmia incidence suggests that current clinical protocols for rhIL-11 may need re-evaluation. Close cardiac monitoring, including regular BNP checks and ECGs, should be considered for patients on rhIL-11, especially if treatment extends beyond two weeks. Clinicians may need to weigh the benefits of prolonged rhIL-11 against the escalating risk of severe cardiac events, potentially favoring alternative treatments like rhTPO for longer durations or in high-risk patients. This finding could directly influence prescribing practices and patient management strategies.
rhil-11
thrombocytopenia
cardiac-toxicity
arrhythmia
bnp
rhtpo